fbpx Skip to main content

Clinical Trials in Australia: 41% Cash Rebate, Streamlined Regulatory Process, & World Class Quality


July 18, 2018 11:30 amJuly 18, 2018 1:00 pm (PDT)


Nixon Peabody
300 South Grand Avenue
Los Angeles, CA 90071

Registration Closed

Please join us for a lunch and learn to learn more about running clinical trials in Australia. Speak with a member of the LA biotech community who has been doing trials in Australia, Ryan Witt, from Immix. Hear discussions on his ongoing experience Down Under. Also presenting will be Stewart Walker from CoSec Consulting, a Melbourne-based service provider that helps US companies fulfill all the compliance requirements and to maximize their eligibility for the R&D rebate program.

Many US biotech companies have decided to do early stage clinical trials in Australia for three primary reasons.
  • The regulatory environment is simplified. In-human trials can commence in the fraction of the time it takes to secure an IND in the US—typically in a matter of weeks.
  • The quality of the work done in Australia is excellent, and all data collected will be recognized by the FDA.
  • The Australian government will give small biotech companies a 41% cash rebate on all eligible R&D expenditures.

Price of Admission

Biocom Event

Today’s Price: 0

Important Dates


Registration before

Registration before

Registration before

Registration cost


Refund before 2018-07-18


Refund before

Refund Before

Registration Closed